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Cistinúria é uma alteração genética autossômica recessiva caracterizada por transporte 
intestinal e renal anormal tubular de L-cistina, assim como de L-lisina, L-arginina e L-ornitina. 
Esta alteração leva a excreção urinária excessiva destes aminoácidos com a formação de pedras 
nos rins provocados pela baixa solubilidade de L-cistina na urina. Neste trabalho, um método 
analítico para a determinação destes quatro aminoácidos por eletroforese capilar acoplada à 
espectrometria de massas com ionização por electrospray (CE-ESI-MS) foi desenvolvido e 
validado. Usando soluções padrão de L-cistina, L-lisina, L-arginina e L-ornitina, os limites de 
detecção dos aminoácidos por este método foram 114,2, 61,3, 72,7 e 86,7 µmol L-1. Soluções 
padrão foram amostrados em um capilar de sílica (50 µm de diâmetro interno e 70 cm de 
comprimento total) e injeção de 2 psi de pressão por 10 s. A separação ocorreu a 300 V cm-1, 
utilizando 1,0 mol L-1 de ácido fórmico em 10% de metanol em água como eletrólito de separação. 
Aplicação do método para a urina de um paciente diagnosticado clinicamente como portador 
de cistinúria revelou a presença de 900,5 ± 5, 600,0 ± 2, 700,2 ± 1 e 500,0 ± 3 µmol L-1 de 
aminoácidos, respectivamente, e 75,3 ± 1 µmol L-1 de creatinina. O método de CE-ESI-MS 
descrito neste trabalho para a análise de L-cistina e outros aminoácidos associados com 
cistinúria constitui uma ferramenta para diagnóstico sensível e confiável para caracterização e 
monitoramento desta doença.
Cystinuria is an autosomal recessive genetic disorder characterized by abnormal intestinal and 
renal tubular transport of L-cystine as well as of L-lysine, L-arginine and L-ornithine. This leads 
to excessive urinary excretion of amino acids, with the formation of kidney stones caused by 
the low solubility of L-cystine in the urine. In this study, an analytical method for simultaneous 
determination of these four amino acids in urine by capillary electrophoresis coupled to 
electrospray ionization mass spectrometry (CE-ESI-MS) was developed and validated. Using 
standard solutions of L-cystine, L-lysine, L-arginine and L-ornithine, the amino acid detection 
limits by this method were 114.2, 61.3, 72.7 and 86.7 µmol L-1. Standard solutions were injected 
in a silica capillary column (50 mm i.d. and 70 cm length) under 2 psi of pressure by 10 s. The 
separation occurred at 300 V cm-1, using 1.0 mol L-1 formic acid in 10% methanol in water as the 
background electrolyte. The method was applied to the urine of a patient clinically diagnosed 
as a cystinuria carrier, which revealed the presence of 900.5 ± 5, 600.0 ± 2, 700.2 ± 1 and 
500.0 ± 3 µmol L-1 of amino acid, respectively, and 75.3 ± 1 µmol L-1 of creatinine. The 
CE-ESI-MS method described here for analyzing L-cystine and other cystinuria-related amino 
acids is a sensitive and reliable diagnostic tool for characterizing and monitoring this disease.
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Introduction
Capillary electrophoresis coupled to mass spectrometry 
(CE-MS) emerged more than two decades ago.1-3 The 
success of this analytical system is due to the combination 
of its high resolution, universal application, efficiency and 
good sensitivity when compared to other detection systems 
such as spectrophotometry in the UV-Visible region, the 
most popular technique, and laser induced fluorescence 
(LIF) which provides high sensitivity. However, both 
techniques cannot unveil the structure of the analyte.4,5 
CE is one of the main techniques used in the separation of 
ionized and neutral analytes. The capillary electrophoresis 
coupled to electrospray ionization mass spectrometry (CE-
ESI-MS) has rapidly developed as a powerful analytical 
tool for charged species analysis of small molecules such 
as carboxylic acids, phenols, metal species, tetramines, 
herbicides, drugs, metabolites, proteins, amino acids and 
peptides. While CE confers rapid analysis and efficient 
resolution, MS frequently allows analyte identification 
with high selectivity and sensitivity. ESI has proven to be 
versatile and relatively easy to use in combination with 
CE.6,7
There is a great interest to determine biochemically active 
metabolites in biological samples aiming at understanding 
the molecular bases of the clinical manifestations of human 
disorders. A large number of amino acid catabolites has 
been suggested as biomarkers of various diseases. Errors 
in metabolism (EM) are diseases that typically result from 
a change in the structure of an enzyme or a protein, leading 
to abnormal catabolism/anabolism of certain carbohydrates, 
amino acids, nucleobases or organic acids. The symptoms 
of many of these diseases are lethargy, poor appetite, 
sleep apnea, frequent vomiting, and if not detected early, 
it can lead to mental retardation or death.8 Recently, with 
the development of MS-ESI, it is possible to use a single 
test to identify a wide range of rare metabolic illnesses.9,10 
Cystinuria is an inborn error of metabolism resulting 
from an autosomal recessive genetic disorder, which 
impairs intestinal and renal tubular transport involving 
L-cystine, L-lysine, L-arginine and L-ornithine, leading 
to excessive urinary excretion of these amino acids, with 
the consequent formation of kidney stones due to the low 
solubility of cystine in the urine.11,12 Urinary obstruction 
causes discomfort, pain, infections and eventually renal 
failure.13 In its heterozygous form, there is a moderate loss 
of these amino acids, but in its homozygous form, there is 
massive excretion of amino acids.14 This genetic disorder 
is related to the three mutant alleles I, II and III present 
in chromosomes 2 or 19, which determine the intestinal 
absorption changes of L-cystine, L-lysine, L-arginine and 
L-orthinine. Cystinuria prevalence ranges from 1/60,000 for 
heterozygous and 1/20,000 for homozygous patients,11 and 
its incidence in humans displays ethnic variations. 
Early and accurate detection and quantification of the 
cystinuria-related metabolites are needed for the successful 
prevention and effective long-term treatment of patients. 
In its homozygous form, the formation of kidney stones 
is recurrent, being difficult to be removed by surgery or 
drugs. Cystinuria should be suspected especially when 
the first stones are formed in the patient in the first two 
decades of life and in subjects with family history of this 
disorder, the highest incidence occurring in the first year of 
life and after puberty. The faster it is correctly diagnosed, 
the greater the success rate in treating the patient. Normal 
concentration of cystine in the urine is below 30 mg per day 
(0.13 mmol per day), homozygous concentration is greater 
than 400 mg per day (1.7 mmol per day) and heterozygous 
concentration varies from 200 to 400 mg per day (0.8 to 
1.7 mmol per day).15 Lindell et al.16 reported an increased 
incidence of urinary stone formation when L-cystine 
concentration in urine is above 700 mmol L-1.17
In the present work, it is studied and developed a 
method for the urinary determination of cystine and other 
pathologically related amino acids using CE-MS in order to 
rapidly and unnequivocally diagnose cystinuria and prevent 
urinary stones. The literature reports only methods for 
cystinuria using liquid chromatography-mass spectrometry 
(LC-MS)18-20 and gas chromatography/mass spectrometry 
(GC-MS).21,22 CE has already been successfully explored as 
a separation technique, but using other detectors instead of 
MS, which brings about important analytical limitations.23,24 
Methods based on HPLC separation consume more 
reagents and produce more solvent waste than CE, whereas 
CE-MS constitutes a more sustainable analytical process.
Currently in Brazil, only five diseases related to errors 
of metabolism are monitored by the public health system, 
cystinuria is not included. The diagnosis of metabolic 
disorders is frequently performed by neonatal screening, 
but many rare genetic diseases can only be detected by 
sophisticated and expensive methods that are only available 
in some private hospitals. Thus, our group proposes here 
the CE-MS technique to diagnose cystinuria through a 
method that was developed and validated to analyze urine 
samples from both healthy donors and cystinuria patients.
Experimental
Reagents and samples
All reagents used were of analytical grade. CE separation 
used formic acid and methanol purchased from Merck 
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(Darmstadt, Germany). Standard samples of L-cystine, 
L-lysine, L-ornithine, L-arginine and L-tryptophan 13C15N 
(internal standard), purchased from Sigma-Aldrich (Saint 
Louis, USA), were prepared in Milli-Q purified water 
(Billerica, USA, USA).
Preparation of standard solutions and electrolytes
Addition of 10% methanol to the electrolyte composition 
showed to be necessary. The solution was prepared by 
diluting the appropriate volume of formic acid with water 
purified by Milli-Q (Billerica, USA). The solutions were 
all filtered using 0.22 mm pore size Millipore disposable 
nylon filters prior to use. The stock standard solutions 
of 5.0 mg L-1 of L-cystine, L-lysine, L-ornithine and 
L-arginine were dissolved in 2.0 mol L-1 formic acid to 
achieve the desired concentration. The internal standard 
was prepared with 0.45 mg mL-1. All solutions were stored 
at 4 °C.
Urine samples
Urine samples were randomly collected from normal 
individuals (n = 10) and cystinuria carriers (n = 1) 
under documented consent and stored at -4 °C until 
use. The ethical guideline number is 1545/10. Samples 
were thawed and centrifuged at 400 g (Eppendorf 
centrifuge 5402, USA) at 4 °C for 10 min. The 
supernatant was filtered through a Millipore membrane 
0.22 mm and sonicated (Elma Ultrasonic Digital S, USA) 
for 20 min.
Capillary electrophoresis conditions
Urine analyses were carried out in a CE system model 
P/ACE MDQ from Beckman Coulter (USA), using 
silica capillaries from Polymicro Technologies (USA) of 
50 µm i.d. and 70 cm length. All amino acid standards and 
urine samples were injected under 2 psi pressure for 10 s. 
The separation occurred at 300 V cm-1 and using 1.0 mol L-1 
formic acid in 10% methanol in water as the background 
electrolyte in CE.
Mass spectrometry conditions
Identification and quantification of the target analytes 
were performed on a Thermo LCQ Advantage MAX ion 
trap mass spectrometer (USA) coupled to the CE apparatus 
through an orthogonal electrospray interface. The Sheath 
liquid used was 49.5% of methanol and 0.5% of acetic acid 
in water. Conditions for ESI-MS analysis were: 4.5 kV, 
ESI temperature 275 ºC, N2 pressure 2 bars. Optimization 
of the MS analysis of the cystinuria-related amino acids 
was obtained by employing the following parameters: 
source current, 80.00 mA; capillary voltage, 3.00 V; 
tube lens voltage offset, -5.00 V; multipole RF amplifier 
(Vp-p), 400.00 Vp-p, multipole 1, voltage offset, -3.50 V; 
multipole 2 voltage offset, -6.50 V, inter multipole lens 
voltage, -20.00 V, trap DC off set voltage, -10.00 V, and 
zoom micro, 5.
FT-Raman studies
FT-Raman spectra were obtained by a Bruker 
RFS-100/S, using a Nd/YAG laser as exciting source at 
1064 nm (Germany). Neat cystine was introduced into the 
sample holder as a pressed pellet and the laser power was 
set to 200 mW. Cystine microcrystals of the urine sample 
were transferred to a glass slide for examination under 
optical microscopy (Ramanscope, Germany) attached to 
the spectrometer, with the laser power set to 400 mW. In 
all cases, the spectral resolution employed was 4 cm-1 and 
128 scans were co-added to trace each spectrum.
Determination of creatinine
CE baseline separation was attained with 25 mmol L-1 
Tris buffer (pH 2.5) as electrolyte in a bare fused silica 
capillary (40 cm total length and 10 cm effective length, 
50 µm i.d.) under 10 kV potential with short-end injection 
configuration using 0.3 psi pressure, and 0.5 s. Urine 
samples were diluted 40-fold with water prior to analysis 
by CE.25,26 The creatinine determination used CE with UV 
detection (l = 205 nm).
Statistical analysis
For statistical treatment of the data presented the 
software OriginPro 8.5.1 was used. Student t-test was used 
to check the deviations from linearity.
Results and Discussion
The optimized and validated methodology proposed 
here for the determination of L-cystine, L-arginine, 
L-ornithine and L-lysine in urine is supported by the 
analytical parameters (specificity, linearity, precision, 
accuracy, limits of detection (LOD) and of quantification 
(LOQ)) required by the Brazilian National Health 
Surveillance Agency (ANVISA)27 and the US FDA 
(Food and Drug Administration Guidance for Industry: 
Bioanalytical Method Validation).28
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Background electrolyte and organic solvent effects
Different buffering conditions suitable for CE-MS were 
tested to attain optimal conditions to separate all amino acids 
excreted in cystinuria patients. The signal-to-noise (S/N) 
ratios, peak resolution and migration times (7-9 min) were 
obtained by using 1.0 mol L-1 formic acid as electrolyte. 
The addition of organic solvents, such as methanol (10%), 
to the background electrolyte considerably improved 
resolution and migration times of the amino acid peaks 
(Figure 1). The migration time increased, once addition of 
organic solvents contributes to decrease the electroosmotic 
flow, thereby promoting better separation, and methanol 
improves the ionization process, consequently increasing 
the S/N ratio.
Pressure effect
Pressure was applied during the electrophoretic 
separation in order to reduce the analysis time. The 
pressures of 2, 3 and 6 psi were tested for 10 s each 
injection. The best running time (10 min) and peak 
resolution were reached with 2 psi. Other pressure values 
resulted in poorer separation resolution.
Specificity
The specificity of the method was evaluated by 
analyzing urine samples with the addition of authentic 
L-cystine, L-arginine, L-lysine and L-ornithine to assess 
the medium interference in the quantification and retention 
times of the amino acids and internal standards. The results 
were then compared with those obtained with an aqueous 
solution of the same standards at different concentrations. 
No changes were observed for retention times and analyte 
quantification.
Linearity
Calibration curves were obtained by tracing the 
electropherograms with MS spectrum detection of each 
amino acid. A linear dependence of peak area on the 
analyte concentration (3.5-225.0 µg mL-1) was verified. The 
respective linear correlation coefficients (r2) were all above 
0.99, thus confirming a significant linearity of the method 
(Table 1). Standard amino acid and patient samples were 
supplemented with an internal standard solution containing 
0.45 mg mL-1 of tryptophan 13C15N, representing 10% of 
total sample volume. As the observed tabulated T values 
are smaller than the calculated ones (Table 1), one can rely 
on a statistically significant correlation between data and 
calibration curve with a confidence level of 95%.
Accuracy
The accuracy was evaluated by the repeatability and 
inter-day precision of the method by expressing the results 
as the coefficient of variation (CV in %). To determine 
repeatability, solutions containing 450.0, 112.5 and 
28.1 µg mL-1 of each amino acid were prepared and the 
concentrations defined as 100% accurate. Five successive 
determinations were conducted for each solution in a 
Figure 1. CE-MS base peak electropherograms of cystinuria-related 
amino acids at a concentration of 45 µg mL-1. Peak identification, 
A: internal standard (L-tryptophan 13C15N), B: L-cystine, C: L-lysine, 
D: L-arginine and E: L-ornithine. Peaks reconstructed according to 
the ratio m/z of analytes and their respective migration time obtained 
under the experimentally established conditions. Conditions for ESI-MS 
analysis were: 4.5 kV, temperature 275º C and N2 pressure 20 bars. Silica 
capillary without internal coating, 50 µm i.d. and 70 cm length. Sample 
volume injected: 20 nL. The separation occurred at 300 V cm-1 and 2 psi 
pressure for 10 s. The background electrolyte CE was 1.0 mol L-1 formic 
acid in 10% of methanol in water. Mass full scan: m/z 100-300 ratio at 
the positive mode.
Table 1. Parameters of the calibration curves and student t-test
Amino acid Equation: y = bx + a r² N Tc Tta
L-Cystine y = 0.7387x + 0.0170 0.9993 5 65.4425 3.1824
L-Arginine y = 0.7993x + 0.0406 0.9935 7 27.6662 2.5706
L-Lysine y = 0.4032x + 0.0080 0.9997 8 134.818 2.4469
L-Ornithine y = 0.4026x + 0.0105 0.9933 8 29.8249 2.4469
aValues obtained by student t-test distribution (n = 5); r²: correlation coefficient; Tc: value calculated; Tt: value table.
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single day under the same conditions. Their respective 
mean values and coefficients of variation are expressed 
in Table 2.
Inter-day precision was studied by analyzing all amino 
acid solutions at a concentration of 112.5 µg mL-1 on two 
consecutive days, performing 5 determinations each day. 
The values of variation coefficients were below 1.5% 
(L-cystine = 0.81%, L-arginine = 0.48%, L-lysine = 0.83%, 
L-ornithine = 1.25%), thus conforming satisfactory 
repeatability values. The ANVISA regulation27 considers 
a method accurate when its coefficient of variation is 
below 15%.
LOD and LOQ
The LOD and LOQ values were determined according 
to the ANVISA regulation,27 which are based on three 
times the noise baseline for estimating LOD and ten 
times for LOQ, both values calculated from the slope of 
calibration curve of each amino acid. Thus, the method 
proved to be reliable and valuable to quantify the cystinuria 
related metabolites regarding sensitivity. The major 
contribution of a specific, sensitive and accurate method for 
cystinuria diagnostics is the prevention of urinary stones. 
Lindell et al16 reported an increase in the incidence of 
urinary stone formation when the L-cystine concentration 
is above 700 mmol L-1. Therefore, the LOQ data listed in 
Table 3 show that the method described here is efficient 
to quantify the amino acids involved in cystinuria for the 
diagnosis and treatment of patients.
Accuracy
The accuracy of the method defined here as the closeness 
between experimental data and nominal values of amino 
acid concentrations related to cystinuria was evaluated 
from synthetic urine (inorganic solutions that simulated 
urine) using three analyte concentrations and performing 
5 times each analysis. Synthetic and medication-free real 
urine samples display the same analytical parameters 
according to FDA28 and ANVISA27 parameters. Table 2 
shows the data used for accuracy evaluation and respective 
coefficients of variation.
Analysis of real urine samples
The analysis of urine samples from healthy donors was 
performed by adding three different standard concentrations 
of cystinuria-related amino acids and a reference sample. 
Each sample was analyzed five times and the metabolites 
were quantified. The amino acid recovery values in the urine 
of healthy donors and respective coefficients of variation 
Table 2. Accuracy, recovery and repeatability parameters for quantifications by CE-MS method developed for the quantification of amino acids in the 
urine of donors
Amino acid Concentration
a
 / 
(µg mL-1) Accuracy / % CV
b
 / % Recovery / % CVb / %
Repeatability 
parameters for 
quantificationa / %
CVb / %
L-Cystine 28.1 127.1 3.8 113.2 8.4 97.1 2.0
112.5 154.8 2.7 109.2 7.2 99.0 3.8
450.0 129.4 6.0 112.9 6.4 99.9 4.3
L-Arginine 28.1 108.8 4.1 110.7 5.0 101.0 4.2
112.5 121.5 4.5 114.5 4.1 103.5 2.0
450.0 114.4 5.0 105.0 5.0 98.0 0.9
L-Lysine 28.1 114.9 4.3 111.0 7.5 105.8 4.8
112.5 103.4 4.1 106.2 6.3 108.1 4.6
450.0 105.9 4.9 108.1 5.4 99.4 4.6
L-Ornithine 28.1 110.5 2.0 98.5 2.5 100.7 4.9
112.5 97.0 4.4 110.5 5.3 106.4 4.1
450.0 98.5 3.6 93.9 3.6 96.4 4.8
aAverage of 5 determinations; bCV: coefficient of variation.
Table 3. Limits of detection (LOD) and of quantification (LOQ) obtained 
from the calibration curves of amino acids
Amino acid LOD / (µmol L-1) LOQ / (µmol L-1)
L-Cystine 114.2 219.0
L-Arginine 71.3 234.5
L-Lysine 30.7 110.0
L-Ornithine 86.7 202.8
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are shown in Table 2. The accuracy of the method applied 
to synthetic urine and the recovery indices in the urine of 
donors were highly acceptable. In summary, the values 
found for the urine sample analysis were reproducible; the 
coefficients of variation were within the allowable limit 
for all biomarkers analyzed, there was no interference 
from other metabolites eventually present in the urine 
samples, and sample desalting was not required.
Analysis of patient samples by CE and CE-ESI-MS
Cystine and other cystinuria-related amino acids 
as well as creatinine were determined in the urine of a 
2.8 years old male cystinuria patient. Total urine was 
collected randomly and the analyses were immediately 
performed. The amino acids were quantified by the same 
procedure used to analyze the standards. Creatinine was 
found to be 75.3 ± 1 µmol L-1 in the urine sample 40-fold 
diluted. The concentrations obtained for L-cystine, 
L-arginine, L-lysine and L-ornithine were 900.5 ± 5, 
600.0 ± 2, 700.2 ± 1 and 500.0 ± 3 µmol L-1, respectively.
Analysis by FT-Raman
The formation of crystals in the patient urine after 
collection and storage at 4 °C was a strong evidence of 
a high urinary concentration of cystine. The FT-Raman 
technique was used prior to CE-ESI-MS identification for 
qualitative characterization of the crystals precipitated in 
the patient urine. Figure 2 shows the close matching of the 
FT-Raman spectrum of authentic cystine crystal samples 
with that of the microcrystals collected from the urine 
of the cystinuria patient. The most prominent FT-Raman 
bands of cystine microcrystals are 498 cm-1 (assigned to the 
characteristic ν (S-S) stretching,29 and other peaks at 105, 
201, 457, 617, 678, 785, 1339, 1408, 2915 and 2966 cm-1.
Conclusion
Here, a specific, sensitive and reliable CE-ESI-MS 
method is optimized and validated for clinical analysis of 
cystinuria through the determination of L-cystine, L-lysine, 
L-arginine and L-ornithine in standard solutions prepared 
with urine and also in a patient urine sample.
Our results attest great potential to the method for use 
in the public health system. All analytical parameters of 
this method are in accordance with the regulations of the 
sanitary inspection agencies, with the LOD values much 
lower than the urinary concentration of amino acids found 
in healthy individuals. Another important advantage of 
the CE-MS method is the reduced use of solvent, which 
makes it environmentally more sustainable than those that 
use HPLC separation. Only patients with abnormally high 
levels of cystine are subjected to the formation of kidney 
stones, hence the need to monitor the levels of urinary 
cystinuria-related amino acid concentrations by rapid, 
sensitive and reliable methods such as the one described 
here to prevent pain discomfort and complications derived 
from surgery.
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